2013


To access this material please log in or register

Register Authorize
2013/№3

Felodipine: myths and reality of evidence-based medicine

Averin E. E.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: calcium channel blockers, vasoselectivity, lercarnidipine, kidney protection, felodipine

DOI: 10.18087/rhj.2013.3.1836

Calcium channel blockers (CCB) are extensively used in clinical practice. Long history of using this class of medicines has not only provided significant experience but also produced some prejudice. Felodipine is one of actively used CCB. This article is focused on a comprehensive analysis of evidence supporting the use of Felodipine in clinical practice.
  1. Марцевич С. Ю. Роль антагонистов кальция в современном лечении сердечно-сосудистых заболеваний. РМЖ. 2003;11 (9):539–541.
  2. Глезер М. Г., Сайгитов Р. Т. Арифон ретард в лечении женщин с артериальной гипертонией. Результаты эпидемиологического исследования АФИНА. Consilium Medicum. 2009;11 (1):21–29.
  3. McMurray JJ, Adamopoulos S, Anker SD et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14 (8):803–869.
  4. Dworkin LD, Tolbert E, Recht PA et al. Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension. 1996 Feb;27 (2):245–250.
  5. Harris DC, Hammond WS, Burke TJ, Schrier RW. Verapamil protects against progression of experimental chronic renal disease. Kidney Int. 1987;31 (1):41–46.
  6. Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int. 1991;39 (6):1112–1127.
  7. Wenzel UO, Troschau G, Schoeppe W et al. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension. 1992;20 (2):233–241.
  8. Ruggenenti P, Perna A, Loriga G et al. The REIN-2 Study Group. Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet. 2005;365 (9463):939–946.
  9. Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant. 2001;16 (11):2158–2165.
  10. Schmitz A. Acute renal effects of oral felodipine in normal man. Eur J Clin Pharmacol. 1987;32 (1):17–22.
  11. Lernfelt B, Landahl S, Johansson P et al. Haemodynamic and renal effects of felodipine in young and elderly subjects. Eur J Clin Pharmacol. 1998;54 (8):595–601.
  12. Hasselgren B, Edgar B, Johnsson G, Rönn O. The acute haemodynamic and renal effects of oral felodipine and ramipril in healthy subjects. Eur J Clin Pharmacol. 1993;45 (4):327–332.
  13. Huysmans FT, van Hamersvelt HW, Sluiter HE et al. Acute renal effects of felodipine in hypertensive patients with kidney disease. Kidney Int Suppl. 1992;36: S106–109.
  14. Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs. 2003;63 (15):1535–1548.
  15. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int. 2007;72 (12):1429–1447.
  16. Sørensen SS, Skovbon H, Eiskjaer H et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol Dial Transplant. 1992;7 (1):69–78.
  17. Pedersen EB, Madsen JK, Sørensen SS, Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney Int Suppl. 1996;55: S94–96.
  18. Madsen JK, Sørensen SS, Hansen HE, Pedersen EB. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant. 1998;13 (9):2327–2334.
  19. Angelico P, Guarneri L, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4‑dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol. 1999;51 (6):709–714.
  20. Sarsero D, Fujiwara T, Molenaar P, Angus JA. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists. Br J Pharmacol. 1998;125 (1):109–119.
  21. Angus JA, Sarsero D, Fujiwara T et al. Quantitative analysis of vascular to cardiac selectivity of L- and T-type voltage-operated calcium channel antagonists in human tissues. Clin Exp Pharmacol Physiol. 2000;27 (12):1019–1021.
  22. Little WC, Cheng CP, Elvelin L, Nordlander M Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drugs Ther. 1995;9 (5):657–663.
  23. Little WC, Cheng CP Vascular versus myocardial effects of calcium antagonists Drugs. 1994;47 (Suppl 4):41–45.
  24. Nordlander M, Abrahamsson T, Akerblom B, Thalén P Vascular versus myocardial selectivity of dihydropyridine calcium antagonists as studied in vivo and in vitro Pharmacol Toxicol. 1995;76 (1):56–62.
  25. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24‑hour ambulatory blood pressure recordings. Curr Ther Res 2001;62 (4):236–253.
  26. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 1998;351 (9118):1755–1762.
  27. Liu L, Zhang Y, Liu G et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23 (12):2157–2172.
  28. Brun J, Fröberg L, Kronmann P et al. Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. J Cardiovasc Pharmacol. 1990;15 (Suppl 4):S60–64.
  29. Агеев Ф. Т., Деев А. Д. Применение фелодипина в амбулаторной практике: оценка клинической эффективности и приверженности к лечению у больных артериальной гипертензией. Кардиология. 2009;49 (1):30–33.
  30. Podjarny E, Korzets Z, Bernheim J. Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring. J Hum Hypertens. 1996;10 (Suppl 3):S153‑S156.
  31. Диагностика и лечение артериальной гипертонии. Российские рекомендации (третий пересмотр) 2008 г. Кардиоваскулярная терапия и профилактика. 2008;6 (Приложение 2). Доступно на: www.cardiosite.ru / recommendations / 2008.
Averin E. E. Felodipine: myths and reality of evidence-based medicine. Russian Heart Journal. 2013;12(3):167-171

To access this material please log in or register

Register Authorize
Ru En